CG Oncology Inc (CGON) ニュース

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

IRVINE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical...

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates

– Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec

IRVINE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical...

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC

– Final positive CORE-001 safety and efficacy findings were published simultaneously online by Nature Medicine...